Treatment with semaglutide can lead to resolution of nonalcoholic steatohepatitis in people with or without type 2 diabetes, show phase 2 trial findings, although a question mark remains over its effect on fibrosis.
Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.